Barclays’s Pliant Therapeutics PLRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$486 Buy
426
+392
+1,153% +$477 ﹤0.01% 5011
2026
Q1
$43 Sell
34
-10,550
-100% -$13.3K ﹤0.01% 4968
2025
Q4
$12.9K Sell
10,584
-358,972
-97% -$539K ﹤0.01% 4914
2025
Q3
$547K Buy
369,556
+356,670
+2,768% +$544K ﹤0.01% 3755
2025
Q2
$14.9K Sell
12,886
-59,026
-82% -$83.4K ﹤0.01% 4875
2025
Q1
$97.1K Sell
71,912
-29,911
-29% -$182K ﹤0.01% 4423
2024
Q4
$1.34M Sell
101,823
-319,676
-76% -$4.36M ﹤0.01% 3180
2024
Q3
$4.73M Buy
421,499
+78,575
+23% +$983K ﹤0.01% 2148
2024
Q2
$3.69M Sell
342,924
-17,221
-5% -$222K ﹤0.01% 1722
2024
Q1
$5.37M Buy
360,145
+7,248
+2% +$120K ﹤0.01% 1796
2023
Q4
$6.39M Buy
352,897
+108,631
+44% +$1.65M ﹤0.01% 1889
2023
Q3
$4.24M Buy
244,266
+152,190
+165% +$2.64M ﹤0.01% 1419
2023
Q2
$1.67M Buy
92,076
+80,295
+682% +$1.9M ﹤0.01% 1997
2023
Q1
$313K Sell
11,781
-14,734
-56% -$419K ﹤0.01% 3556
2022
Q4
$513K Buy
26,515
+20,919
+374% +$437K ﹤0.01% 3299
2022
Q3
$117K Sell
5,596
-6,013
-52% -$115K ﹤0.01% 3477
2022
Q2
$93K Sell
11,609
-3,874
-25% -$24.8K ﹤0.01% 3796
2022
Q1
$109K Buy
+15,483
New +$158K ﹤0.01% 3738

Other funds holding PLRX

Barclays's PLRX Position: Q2 2026 in Review

Barclays increased its Pliant Therapeutics (PLRX) stake by 1,153% in Q2 2026, buying an estimated $477 and bringing the position to 426 shares worth $486. The position accounts for ﹤0.01% of the portfolio, ranked #5011.

Barclays first reported a position in PLRX in Q1 2022 and has held it in 18 quarters since. The position peaked at $6.39M in Q4 2023. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

  • Barclays held 426 shares of Pliant Therapeutics worth $486 as of Q2 2026.
  • Barclays bought 392 Pliant Therapeutics shares in Q2 2026, an estimated $477.
  • Pliant Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5011 holding.
  • Barclays first reported a position in Pliant Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Pliant Therapeutics position peaked at $6.39M in Q4 2023.
  • 86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.